From Wikipedia, the free encyclopedia
Medication
Viqualine
|
|
4-[3-[(3R,4R)-3-Ethenylpiperidin-4-yl]propyl]-6-methoxyquinoline
|
CAS Number | |
---|
PubChem
CID | |
---|
ChemSpider | |
---|
UNII | |
---|
ChEMBL | |
---|
|
Formula | C20H26N2O |
---|
Molar mass | 310.441 g·mol−1 |
---|
3D model (
JSmol) | |
---|
COC1=CC2=C(C=CN=C2C=C1)CCC[C@@H]3CCNC[C@@H]3C=C
|
InChI=1S/C20H26N2O/c1-3-15-14-21-11-9-16(15)5-4-6-17-10-12-22-20-8-7-18(23-2)13-19(17)20/h3,7-8,10,12-13,15-16,21H,1,4-6,9,11,14H2,2H3/t15-,16+/m0/s1 NKey:XFXANHWIBFMEOY-JKSUJKDBSA-N N
|
NY
(what is this?)
(verify) |
Viqualine (
INN) (developmental code name PK-5078) is an
antidepressant and
anxiolytic
drug that was never marketed.
[1]
[2]
[3] It acts as a potent and selective
serotonin releasing agent and
serotonin reuptake inhibitor.
[3]
[4] In addition, viqualine displaces
diazepam from the
GABAA receptor and produces
benzodiazepine-like effects, indicating that it is also a
positive allosteric modulator of the benzodiazepine site of the GABAA receptor.
[3]
[5] The drug has mainly been researched as a potential treatment for
alcoholism.
[6]
[7]
See also
References
-
^ Elks J (14 November 2014).
The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 1–.
ISBN
978-1-4757-2085-3.
-
^ Faravelli C, Albanesi G, Sessarego A (1988). "Viqualine in resistant depression: a double-blind, placebo-controlled trial". Neuropsychobiology. 20 (2): 78–81.
doi:
10.1159/000118477.
PMID
3075725.
- ^
a
b
c Papakostas GI, Fava M (2010).
Pharmacotherapy for Depression and Treatment-resistant Depression. World Scientific. pp. 304–.
ISBN
978-981-4287-59-3.
-
^ Le Fur G, Imbault F, Mitrani N, Marquis F, Renault C, Dubroeucq MC, et al. (February 1984). "The 5-hydroxytryptamine-releasing properties of two epimer quinoline derivatives". Neuropharmacology. 23 (2A): 169–173.
doi:
10.1016/S0028-3908(84)80010-6.
PMID
6717757.
S2CID
30380886.
-
^ Faravelli C, Albanesi G, Sessarego A (1988). "Viqualine in resistant depression: a double-blind, placebo-controlled trial". Neuropsychobiology. 20 (2): 78–81.
doi:
10.1159/000118477.
PMID
3075725.
-
^ Naranjo CA, Sellers EM (1989). "Serotonin Uptake Inhibitors Attenuate Ethanol Intake in Problem Drinkers". Recent Developments in Alcoholism. Vol. 7. pp. 255–266.
doi:
10.1007/978-1-4899-1678-5_13.
ISBN
978-1-4899-1680-8.
PMID
2522667.
-
^ Naranjo CA, Sullivan JT, Kadlec KE, Woodley-Remus DV, Kennedy G, Sellers EM (September 1989). "Differential effects of viqualine on alcohol intake and other consummatory behaviors". Clinical Pharmacology and Therapeutics. 46 (3): 301–309.
doi:
10.1038/clpt.1989.142.
PMID
2673621.
S2CID
27080094.
|
---|
Alcohols | |
---|
Barbiturates | |
---|
Benzodiazepines | |
---|
Carbamates | |
---|
Flavonoids | |
---|
Imidazoles | |
---|
Kava constituents | |
---|
Monoureides | |
---|
Neuroactive steroids | |
---|
Nonbenzodiazepines | |
---|
Phenols | |
---|
Piperidinediones | |
---|
Pyrazolopyridines | |
---|
Quinazolinones | |
---|
Volatiles/
gases | |
---|
Others/unsorted |
-
3-Hydroxybutanal
-
α-EMTBL
-
AA-29504
-
Alogabat
-
Avermectins (e.g.,
ivermectin)
-
Bromide compounds (e.g.,
lithium bromide,
potassium bromide,
sodium bromide)
-
Carbamazepine
-
Chloralose
-
Chlormezanone
-
Clomethiazole
-
Darigabat
-
DEABL
-
Deuterated etifoxine
-
Dihydroergolines (e.g.,
dihydroergocryptine,
dihydroergosine,
dihydroergotamine,
ergoloid (dihydroergotoxine))
-
DS2
-
Efavirenz
-
Etazepine
-
Etifoxine
-
Fenamates (e.g.,
flufenamic acid,
mefenamic acid,
niflumic acid,
tolfenamic acid)
-
Fluoxetine
-
Flupirtine
-
Hopantenic acid
-
KRM-II-81
-
Lanthanum
-
Lavender oil
-
Lignans (e.g.,
4-O-methylhonokiol,
honokiol,
magnolol,
obovatol)
-
Loreclezole
-
Menthyl isovalerate (validolum)
-
Monastrol
-
Niacin
-
Niacinamide
-
Org 25,435
-
Phenytoin
-
Propanidid
-
Retigabine (ezogabine)
-
Safranal
-
Seproxetine
-
Stiripentol
-
Sulfonylalkanes (e.g.,
sulfonmethane (sulfonal),
tetronal,
trional)
-
Terpenoids (e.g.,
borneol)
-
Topiramate
-
Valerian constituents (e.g.,
isovaleric acid,
isovaleramide,
valerenic acid,
valerenol)
|
---|
|
|
---|
DRAsTooltip Dopamine releasing agents | |
---|
NRAsTooltip Norepinephrine releasing agents | |
---|
SRAsTooltip Serotonin releasing agents | |
---|
Others | |
---|
|